多西他赛联合卡培他滨治疗激素抵抗性晚期前列腺癌的近期疗效

目的探讨多西他赛联合卡培他滨治疗激素抵抗性晚期前列腺癌的近期疗效和毒副反应。方法12例激素抵抗性晚期前列腺癌患者接受以下方案化疗：多西他赛，75mg／m2，静脉滴注，第1天；卡培他滨，每日1250mg／m2，分2次口服，第1～14天；每21天为1个周期。比较化疗前后血清总前列腺特异性抗原（T-PSA）、骨痛评分及可测量病灶的变化等进行近期疗效评估，并了解本化疗方案的不良反应。结果12例中PSA降低反应有效8例，有效率66．67％；8例伴骨痛患者化疗后有6例明显缓解，其NRS疼痛评分平均值由4．38分降至2．63分；3例有可测量转移病灶患者中有2例病灶显著缩小。化疗不良反应主要为骨髓抑制、手足综合征和胃肠道反应等。结论多西他赛联合卡培他滨治疗激素抵抗性晚期前列腺癌有一定疗效，毒副反应可耐受。

Effects of docetaxel and capecitabine for hormone-refractory prostate cancer

Objectives Toinvestigate the role and side effects ofdocetaxel and capecitabine on treatinghormone-refractoryprostate cancer(HRPC).Methods Twelve patients with HRPC were enrolled in this study.Docetaxel (75 mg/m 2,intravenously) on days 1 and capecitabine (1250 mg/m 2 per day in 2 divided doses) on days 1 to 14 were administered in 21-day cycles.The end points were changes in T-PSA,pain score and measurable metastasis.Results Of the 12 patients,a prostate specific antigen response of 50% or greater decrease...